Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Third dose of BNT162b2 vaccine protects against Omicron hospitalizations

A new study assesses the effectiveness of two and three doses of the BNT162b2 vaccine against Omicron-related hospitalizations.

25 Jan 2022

Spike-mediated CFTR inhibition accounts for airway inflammation in COVID-19

A new study looks at the molecular level inhibition of the protective CFTR gene by the SARS-CoV-2 spike protein.

25 Jan 2022

Scientists find reduced vaccine efficacy against Omicron in South Africa and 50 other countries

In a new study, researchers evaluated the impact of the SARS-CoV-2 Omicron variant on the prevalence of SARS-CoV-2 infections among unvaccinated and vaccinated populations of South Africa and 50 other countries.

25 Jan 2022

Growth advantage of SARS-CoV-2 Omicron variant found to be partly due to shorter serial interval

In a new study, a team of researchers assessed how serial intervals of SARS-CoV-2 Omicron and Delta variants varied during the same time period in the Netherlands.

25 Jan 2022

Humoral correlate of protection for SARS-CoV-2 may reduce COVID-19 infection risk

In a new study, a team of researchers reviewed the published literature to find evidence for humoral SARS-CoV-2 correlate of protection (CoP).

25 Jan 2022

Accelerating the COVID-19 booster vaccination rate to prevent Omicron variant hospitalizations and deaths

A new study investigates the impact of accelerating the pace of COVID-19 booster vaccination rates in the US in reducing COVID-19-related hospitalizations and mortalities.

25 Jan 2022

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Scientists have recently used synthetic biology to design primary human CD8 T cells to express Spike protein-specific chimeric antigen receptors (ACE2 CAR or anti-Spike CAR).

25 Jan 2022

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

A new study has focused on the identification, in vitro binding, and potent neutralizing activity of STI-9167 (plutavimab) against live viruses and pseudotype viruses.

25 Jan 2022

Impact of a third BNT162b2 dose on SARS-CoV-2 Omicron variant

In a new study, researchers assessed the extent and duration of the neutralization of SARS-CoV-2 Omicron variant of concern after the administration of two and three doses of the BNT162b2 mRNA vaccine.

25 Jan 2022

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

A new study investigated SARS-CoV-2 spike protein responses targeted by cross-reactive T cells that were isolated from convalescent COVID-19 individuals along with previously uninfected donors.

25 Jan 2022

Study explores individuals’ experiences with long COVID

The current study sought to present the actual face of the condition in experiential terms.

25 Jan 2022

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

The current paper compares the effectiveness of two vs. three doses of these vaccines against Omicron compared to Delta.

25 Jan 2022

Scientists develop a model to rapidly identify vaccine breakthrough SARS-CoV-2 variants

In a new study, scientists have recently developed a computational model to predict the antigenicity and immune escape ability of emerging variants of SARS-CoV-2.

25 Jan 2022

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

A recent study evaluated the sensitivity and specificity of a “spit and mail” serology test.

25 Jan 2022

Study compares exhaled aerosols in SARS-CoV-2 infected individuals and healthy controls

In a new study, exhaled aerosols were compared between infected SARS-CoV-2 patients and healthy controls for the first time. A preprint version of this study, which is yet to undergo peer review, is available on the medRxiv* server.

24 Jan 2022

In Portugal risk of hospitalization from Omicron is 75% lower than Delta

Researchers from Portugal reported a 75% risk reduction in hospitalizations for individuals infected with Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compared to the Delta variant and a shorter length of stay and lower mortality if hospitalization does occur. Their paper is currently available on the medRxiv* preprint server while undergoing peer review.

24 Jan 2022

LA County study finds COVID-19 'herd immunity' unlikely

In a research letter published in the Journal of the American Medical Association (JAMA), researchers carried out a seroprevalence and vaccination coverage study in Los Angeles County (LAC).

24 Jan 2022

Neurological complications of the SARS-CoV-2 vaccine

In a study published in the latest issue of the journal Neurological Sciences, a team of researchers described a three-patient case series presenting with neurological manifestations after the coronavirus disease 2019 (COVID-19) vaccination, followed by a literature review, to propose hypotheses on how neurological symptoms might develop after vaccination.

24 Jan 2022

Danish study shows lower risk of hospitalization in Omicron cases compared to Delta

In a recent study posted to the Preprints with The Lancet* server, a large team of researchers estimated the comparative risk of hospitalization after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron and Delta variants of concern (VOCs) in Denmark.

24 Jan 2022

The long-term neurologic consequences of COVID-19

A team of researchers recently provided insights into central nervous system consequences of the coronavirus disease 2019 (COVID-19) in a perspective paper published in the Science journal.

24 Jan 2022

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Third dose of BNT162b2 vaccine protects against Omicron hospitalizations

Spike-mediated CFTR inhibition accounts for airway inflammation in COVID-19

Scientists find reduced vaccine efficacy against Omicron in South Africa and 50 other countries

Growth advantage of SARS-CoV-2 Omicron variant found to be partly due to shorter serial interval

Humoral correlate of protection for SARS-CoV-2 may reduce COVID-19 infection risk

Accelerating the COVID-19 booster vaccination rate to prevent Omicron variant hospitalizations and deaths

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

Impact of a third BNT162b2 dose on SARS-CoV-2 Omicron variant

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

Study explores individuals’ experiences with long COVID

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

Scientists develop a model to rapidly identify vaccine breakthrough SARS-CoV-2 variants

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

Study compares exhaled aerosols in SARS-CoV-2 infected individuals and healthy controls

In Portugal risk of hospitalization from Omicron is 75% lower than Delta

LA County study finds COVID-19 'herd immunity' unlikely

Neurological complications of the SARS-CoV-2 vaccine

Danish study shows lower risk of hospitalization in Omicron cases compared to Delta

The long-term neurologic consequences of COVID-19

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Newsletters you may be interested in